Insider Transactions in Q4 2022 at Inhibrx, Inc. (INBX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2022
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.15%
|
$256,500
$27.24 P/Share
|
|
Dec 19
2022
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,000
-0.51%
|
$650,000
$25.91 P/Share
|
|
Dec 06
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.61%
|
$1,080,000
$27.62 P/Share
|
|
Nov 21
2022
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.15%
|
$275,500
$29.73 P/Share
|
|
Nov 17
2022
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,000
-0.15%
|
$728,000
$28.78 P/Share
|
|
Nov 01
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.9%
|
$1,320,000
$33.62 P/Share
|
|
Oct 21
2022
|
Jon Faiz Kayyem Director |
SELL
Open market or private sale
|
Indirect |
9,500
-0.15%
|
$275,500
$29.99 P/Share
|
|
Oct 17
2022
|
Mark Lappe Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
26,000
-0.25%
|
$780,000
$30.23 P/Share
|
|
Oct 07
2022
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
1,333,333
+39.59%
|
$39,999,990
$30.0 P/Share
|
|
Oct 04
2022
|
Brendan P. Eckelman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.25%
|
$1,080,000
$27.78 P/Share
|